Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, Butler MO, Cheng T, Romano PM, Pons-Tostivint E, Di Nicola M, Curigliano G, Ryu MH, Rodriguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R. Robbrecht D, et al. Among authors: abbadessa g. Clin Transl Sci. 2024 Feb;17(2):e13736. doi: 10.1111/cts.13736. Clin Transl Sci. 2024. PMID: 38362837 Free PMC article. Clinical Trial.
HER2-low expression in patients with advanced or metastatic solid tumors.
Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. Uzunparmak B, et al. Among authors: abbadessa g. Ann Oncol. 2023 Nov;34(11):1035-1046. doi: 10.1016/j.annonc.2023.08.005. Epub 2023 Aug 22. Ann Oncol. 2023. PMID: 37619847
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: abbadessa g. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Zanghì A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, Abbadessa G, Cellerino M, Ziccone V, Miele G, Lus G, Valentino P, Bucello S, Inglese M, Centonze D, Avolio C, D'Amico E. Zanghì A, et al. Among authors: abbadessa g. J Neurol. 2024 May 4. doi: 10.1007/s00415-024-12360-x. Online ahead of print. J Neurol. 2024. PMID: 38704488
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis.
Abbadessa G, Lepore MT, Bruzzaniti S, Piemonte E, Miele G, Signoriello E, Perna F, De Falco C, Lus G, Matarese G, Bonavita S, Galgani M. Abbadessa G, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200250. doi: 10.1212/NXI.0000000000200250. Epub 2024 Apr 25. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38662990 Free PMC article.
Reply to Wostyn, P. Targeting the Cerebrospinal Fluid Compartment in Glaucoma: Still the Dark Side of the Moon? Comment on "Passaro et al. Glaucoma as a Tauopathy-Is It the Missing Piece in the Glaucoma Puzzle? J. Clin. Med. 2023, 12, 6900".
Passaro ML, Matarazzo F, Abbadessa G, Pezone A, Porcellini A, Tranfa F, Rinaldi M, Costagliola C. Passaro ML, et al. Among authors: abbadessa g. J Clin Med. 2024 Feb 27;13(5):1332. doi: 10.3390/jcm13051332. J Clin Med. 2024. PMID: 38592163 Free PMC article.
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
Maida E, Moccia M, Palladino R, Borriello G, Affinito G, Clerico M, Repice AM, Di Sapio A, Iodice R, Spiezia AL, Sparaco M, Miele G, Bile F, Scandurra C, Ferraro D, Stromillo ML, Docimo R, De Martino A, Mancinelli L, Abbadessa G, Smolik K, Lorusso L, Leone M, Leveraro E, Lauro F, Trojsi F, Streito LM, Gabriele F, Marinelli F, Ianniello A, De Santis F, Foschi M, De Stefano N, Morra VB, Bisecco A, Coghe G, Cocco E, Romoli M, Corea F, Leocani L, Frau J, Sacco S, Inglese M, Carotenuto A, Lanzillo R, Padovani A, Triassi M, Bonavita S, Lavorgna L; Digital Technologies, Web, Social Media Study Group of the Italian Society of Neurology (SIN). Maida E, et al. Among authors: abbadessa g. J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328-x. Online ahead of print. J Neurol. 2024. PMID: 38568227
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Among authors: abbadessa g. Eur J Neurol. 2024 Jun;31(6):e16250. doi: 10.1111/ene.16250. Epub 2024 Mar 28. Eur J Neurol. 2024. PMID: 38549186
141 results